Drug Trial Radar · NCT01229761
Study to Improve Survival Among HIV-Exposed Infants in Botswana
Last checked: Nov 19, 2026Latest source record: Sep 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,724
Planned (sponsor's estimate)
Start
May 2011
Primary completion
Mar 2015
Study completion Oct 2018
Sponsor
- Lead sponsor
- Harvard School of Public Health (HSPH)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Harvard Medical School (HMS and HSDM); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Oct 28, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find ways to improve infant health and survival among infants whose mothers are HIV-infected but who do not themselves have HIV.
Conditions
- HIV Infections
- Neutropenia
- Anemia
Interventions
cotrimoxazole prophylaxisDrug
100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
cotrimoxazole placeboDrug
100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
exclusive breastfeeding until 6 months of ageBehavioral
Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
breastfeeding for 12 monthsBehavioral
Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: 18 months of age
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Princess Marina Hospital
Gaborone, Botswana
Athlone Hospital
Lobatse, Botswana
Scottish Livingstone Hospital
Molepolole, Botswana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.